PwPepwise

Thymulin

Immune Support

Zinc-dependent thymic peptide

Thymulin is a small hormone produced exclusively by the thymus gland — the immune organ responsible for maturing T cells, the white blood cells.

§Dosing at a glance

2 protocols · from the research
What it's forDoseHow oftenHowFor how long
Indirect restoration via zinc supplementation (human studies)200 mg/dayDailyOralTaken by mouth.1 mos
Direct thymulin administration (animal studies only)100 ng/kgDailySubcutaneousInjected just under the skin, into the fat layer.3 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

Thymulin is a small hormone produced exclusively by the thymus gland — the immune organ responsible for maturing T cells, the white blood cells that fight infections and regulate immune responses. It requires zinc to become biologically active, meaning that even when the body produces adequate amounts of the peptide, a zinc deficiency can effectively switch it off4,11,13. Thymulin plays a central role in guiding immature T cells toward full immune competence, and its levels naturally decline with age in parallel with thymic shrinkage14.

In humans, thymulin levels appear to reflect overall immune health: they are lower in zinc-deficient individuals4,9, malnourished children10, and people with hypothyroidism6, and higher in conditions of excess growth hormone3,17. Zinc supplementation in HIV-infected patients has been reported to restore active thymulin levels alongside meaningful reductions in opportunistic infections1,15. Early animal research suggests thymulin may also play a role in reducing inflammation in the lungs12, protecting reproductive function20, and modulating pain signaling19. The evidence base is actively developing, with emerging research exploring thymulin-based gene therapy and peptide analogs as novel therapeutic tools16,20.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Thymulin (also designated FTS — facteur thymique sérique — or Zn-FTS in its active form) is a nonapeptide of sequence Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn produced exclusively by thymic epithelial cells (TECs), as confirmed by its absence in athymic nude animals and thymectomized mice14. Its biological activity is strictly zinc-dependent: zinc binding induces a conformational change in the peptide that creates a unique structural epitope recognized by activity-blocking monoclonal antibodies, while standard RIA and ELISA assays using zinc-deprived substrates detect only a zinc-independent epitope and therefore may underestimate the biologically active fraction13. This zinc dependence means that thymulin circulates in two pools — active zinc-bound ZnFTS and inactive apo-thymulin — and conditions that impair zinc bioavailability functionally reduce thymulin activity without necessarily reducing total peptide levels11,15.

At the cellular level, thymulin promotes differentiation of immature thymocytes into mature, functional T lymphocytes, particularly driving CD4+ T helper cell maturation and supporting Th1-type cytokine responses including IL-2 and IFN-γ production5,9,10. Zinc deficiency selectively impairs Th1 but not Th2 immunity through this pathway, producing a Th1/Th2 imbalance that increases susceptibility to intracellular pathogens5,9. IL-1α and IL-1β regulate the zinc-loading of thymulin in TECs by stimulating zinc uptake — partly independent of cell proliferation — and inducing metallothionein mRNA expression, which provides a molecular bridge between immune activation signals and thymulin bioactivation8. Furthermore, IL-1 is required as a co-signal for zinc-thymulin to activate nuclear protein kinase C in T lymphocytes, indicating that full downstream signaling is gated by the inflammatory cytokine context8.

Thymulin production is regulated by multiple neuroendocrine axes. Growth hormone stimulates thymulin secretion indirectly through a paracrine IGF-1 loop within the thymus — an effect fully abolished by anti-IGF-1 and anti-IGF-1 receptor antibodies — and acromegaly patients exhibit significantly elevated thymulin levels correlating with IGF-13. GH-deficient children show reduced basal thymulin that is restored by exogenous GH administration, with effects lasting at least 48 hours, and the response correlates with IGF-1 rather than GH itself17. Prolactin exerts dose-dependent stimulation of thymulin synthesis and TEC proliferation through what appears to be a PRL-receptor-mediated mechanism rather than a direct GH effect7. Thyroid hormones positively regulate thymulin via a zinc-independent pathway, as demonstrated by thymulin normalization following treatment of both hyper- and hypothyroidism6.

Beyond classical immunomodulation, thymulin and its analogs engage additional signaling pathways. In pulmonary models, thymulin suppresses IL-6 expression and p38 MAPK signaling, producing anti-inflammatory and antifibrotic effects in rodent pulmonary hypertension12 and allergic asthma16 models. A synthetic thymulin-related peptide analog (PAT) directly potentiates α7-nicotinic acetylcholine receptor (α7-nAChR) activity — confirmed electrophysiologically in Xenopus oocytes — connecting thymulin-related signaling to the cholinergic anti-inflammatory pathway and producing anti-hyperalgesic effects in rodent pain models19. Thymulin also appears to play a physiologic role in the hypothalamo-pituitary-gonadal axis, with thymulin restoration in athymic mice preserving GnRH neuron populations, gonadotropic cell counts, and ovarian folliculogenesis20.

§04Evidence & efficacy

Evidence base
260Studies
102Human
83Animal

Thymulin's most replicated human evidence base involves its role as a functional biomarker of zinc status and immune competence. Across multiple human models of mild zinc deficiency, thymulin activity was consistently decreased and restored by zinc supplementation, with parallel normalization of T cell subpopulations and IL-2 activity4,9. Notably, thymulin activity and IL-2 mRNA changes appeared earlier and were more sensitive indicators of zinc deficiency than plasma zinc measurements themselves9.

In HIV/AIDS patients, zinc supplementation appears to restore active zinc-bound thymulin and has been reported to reduce recidivism of opportunistic infections — particularly Pneumocystis carinii and Candida — compared to AZT alone1,15. One randomized trial reported markedly fewer opportunistic infections over 24 months in zinc-supplemented stage IV C1 patients (11 vs. 25 infections) and dramatically delayed infections in stage III patients (1 vs. 13 infections)1.

Thymulin production appears to be regulated by multiple neuroendocrine signals. Growth hormone may stimulate thymulin through a local IGF-1 paracrine mechanism3,17, prolactin appears to stimulate thymulin synthesis in thymic epithelial cells in a dose-dependent manner7, and thyroid hormone status positively correlates with circulating thymulin levels, with treatment of thyroid dysfunction restoring normal thymulin activity6. IL-1 appears to play a co-regulatory role in thymulin zinc-loading and downstream T-lymphocyte signaling8.

In vitro, thymulin has been reported to promote maturation of T lymphocytes from severely malnourished children, reducing immature and increasing mature T cell populations10. In animal models, thymulin administration may prevent pulmonary hypertension-associated cardiopulmonary remodeling through IL-6 and p38 MAPK suppression12, and thymulin gene therapy has been reported to achieve near-complete resolution of established allergic asthma pathology including fibrosis after a single dose16. Thymulin appears to play a physiologic role in the reproductive neuroendocrine axis, with gene therapy restoration of thymulin in athymic mice preventing ovarian dysgenesis and preserving GnRH and gonadotropic cell populations20. A thymulin-related peptide analog (PAT) may exert anti-inflammatory and anti-hyperalgesic effects partly through α7-nicotinic acetylcholine receptor potentiation19.

§05Safety

Human safety data for directly administered thymulin is not yet available in the published literature, as clinical trials of exogenous thymulin peptide have not been reported. The available human evidence pertains to zinc supplementation as a means of restoring endogenous thymulin activity. In two human studies of zinc supplementation (200 mg zinc sulfate/day or 45 mg elemental zinc/day for 30 days in HIV/AIDS patients), no adverse events or tolerability issues were reported1,15.

In animal studies, thymulin administered subcutaneously at 100 ng/kg/day for 3 weeks in rats produced no reported adverse effects, and animals tolerated the treatment without noted complications12. Neonatal adenoviral gene therapy delivering a thymulin analog in mice resulted in no reported adverse events through a 70–71 day follow-up period20. Intratracheal nanoparticle-delivered thymulin gene therapy in mice was similarly reported as well-tolerated, though explicit tolerability data were not detailed16. The thymulin-related peptide analog PAT, administered systemically in rodent models, showed no reported toxicity, and a reverse-sequence control peptide produced no biological effects, confirming sequence-specific rather than nonspecific activity19.

§06History

Thymulin was first isolated and characterized in the 1970s by Jean-François Bach and colleagues at the Necker Institute in Paris, originally termed FTS (facteur thymique sérique — serum thymic factor). It was identified as a nonapeptide secreted by thymic epithelial cells with T lymphocyte-differentiating properties, and its exclusive thymic origin was confirmed by its absence in athymic nude and thymectomized animals14. A key milestone came with the discovery of its strict zinc dependence: the peptide circulates in biologically inactive (apo) and active (zinc-bound, Zn-FTS) forms, and zinc binding was shown through NMR and monoclonal antibody studies to induce a unique conformational epitope essential for hormonal function13. This finding, published in 1985, fundamentally reframed thymulin as a metallopeptide hormone and established that conventional immunoassays might systematically misclassify active hormone status13.

Throughout the late 1980s and 1990s, research expanded to characterize thymulin's neuroendocrine regulation, demonstrating modulatory roles for prolactin7, growth hormone via IGF-13,17, and thyroid hormones6, establishing thymulin as a nexus of immune-endocrine communication. Parallel work by Prasad and colleagues established serum thymulin activity as a sensitive early biomarker of zinc deficiency in humans, more sensitive than plasma zinc itself4,9. Clinical application in HIV/AIDS during the 1990s demonstrated that zinc supplementation restoring active thymulin reduced opportunistic infections1,15. More recently, the field has moved toward gene therapy approaches — delivering thymulin-encoding vectors via nanoparticles or adenoviral vectors — demonstrating therapeutic efficacy in murine asthma16 and reproductive dysfunction models20, with thymulin analog research exploring cholinergic anti-inflammatory mechanisms19.

§07References